DeepMed Research

OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.otsuka-us.com

Clinical Trials

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Brexpiprazole

First Posted Date: 2013-12-17

Last Posted Date: 2016-03-29

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 49

Registration Number: NCT02013622

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

Phase 3

Completed

Conditions: Major Depressive Disorder (MDD)

Interventions: Drug: ADT
Drug: Brexpiprazole

First Posted Date: 2013-12-16

Last Posted Date: 2015-12-29

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 61

Registration Number: NCT02012218

Locations: 🇺🇸
Goldpoint Clinical Research, Indianapolis, Indiana, United States
🇺🇸
St. Louis Clinical Trials, St. Louis, Missouri, United States
🇺🇸
Behavioral Medical Research of Staten Island, Staten Island, New York, United States

and more 20 locations

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Phase 1

Completed

Conditions: Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Interventions: Drug: tolvaptan

First Posted Date: 2013-12-12

Last Posted Date: 2016-05-16

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 30

Registration Number: NCT02009878

Locations: 🇪🇸
Hospital Universitario Clinico San Carlos, Madrid, Spain
🇩🇪
Medizinische Klinik im Klinikum Hannover, Hannover, Niedersachsen, Germany
🇨🇿
Vseobecna fakultni nemocnice V Praze, Praha, Czech Republic

and more 11 locations

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: SEP-363856 Open Label
Drug: Placebo
Drug: SEP-363856

First Posted Date: 2013-11-25

Last Posted Date: 2024-06-26

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 48

Registration Number: NCT01994473

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

Phase 2

Withdrawn

Conditions: Mental Disorder
Bipolar 1 Disorder
Schizophrenia
Nervous System Diseases

Interventions: Drug: Aripiprazole
Device: Ingestible Event Marker (IEM)

First Posted Date: 2013-11-13

Last Posted Date: 2015-04-28

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Registration Number: NCT01981811

Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: SEP-363856
Drug: Amisulpride
Drug: Placebo

First Posted Date: 2013-10-30

Last Posted Date: 2024-06-26

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 105

Registration Number: NCT01972711

Locations: 🇬🇧
University of Manchester, Neuroscience and Psychiatry Unit, Manchester, United Kingdom
🇬🇧
Department of Psychiatry, University of Oxford, Warneford Hospital, Headington, Oxford, United Kingdom

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: SEP-363856

First Posted Date: 2013-09-12

Last Posted Date: 2024-06-26

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 48

Registration Number: NCT01940159

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

Phase 2

Completed

Conditions: Adult ADHD

Interventions: Drug: CTN SR
Drug: Placebo

First Posted Date: 2013-09-11

Last Posted Date: 2021-10-18

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 45

Registration Number: NCT01939353

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

Phase 3

Completed

Conditions: Mental Disorder
Agitation Associated With
Nervous System Diseases
Alzheimer's Disease
Alzheimer's Type

Interventions: Drug: Brexpiprazole, OPC-34712

First Posted Date: 2013-08-14

Last Posted Date: 2020-11-20

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 270

Registration Number: NCT01922258

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

Phase 1

Completed

Conditions: Mental Disorder
Schizophrenia
Nervous System Diseases

Interventions: Drug: Aripiprazole, OPC-14597

First Posted Date: 2013-07-26

Last Posted Date: 2015-07-01

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 141

Registration Number: NCT01909466

Locations: 🇺🇸
Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
🇺🇸
CNRI-San Diego, San Diego, California, United States
🇺🇸
Scientific Clinical Research, Inc., Ft. Lauderdale, Florida, United States

and more 6 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy